Federal regulators have green-lighted the first trial of an embryonic stem-cell treatment in humans. The U.S. Food and Drug Administration (FDA) gave the go-ahead for Geron Corporation to start a phase I safety trial of its therapy GRNOPC1 for spinal cord injuries, the Menlo Park, Calif.–based company announced today. It first sought permission for the trial four years ago and spent much of the last year trying to satisfy the FDA’s concerns about it. "This marks the beginning of what is potentially a new chapter in medical therapeutics—one that reaches beyond pills to a new level of healing: the restoration...
